September 4, 2025 - But for others, treatment could potentially cause thyrotoxicosis (too much thyroid hormone in your body), especially in people 65 years or older. Additionally, most people with subclinical hypothyroidism don’t have symptoms.

Learn about subclinical (borderline) thyroid conditions

February 1, 2019 - Subclinical hypothyroidism can ... present, and has been associated with adverse metabolic, cardiovascular, reproductive, maternal-fetal, neuromuscular, and cognitive abnormalities and lower quality of life....

February 15, 2024 - Still, some individuals can have ... subclinical hypothyroidism (with TSH ≥10 mIU/L) correlates with an increased risk of fatal and non-fatal coronary artery disease (CAD) events, congestive heart failure, and fatal stroke.[8][9][10] The prevalence of this disorder is bound ...

January 23, 2024 - However, if mild hypothyroid symptoms do appear, they may present as: ... A TSH level of 7.0 mIU/L or greater (within the subclinical range) may lead to congestive heart failure.

May 28, 2024 - But slightly elevated TSH levels don’t pose any health risk themselves. TSH levels are often only temporarily higher, for example after intense physical activity. So there is some disagreement about whether and when subclinical hypothyroidism should be treated with hormone tablets.

February 2, 2023 - Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/486813 · Spyridoula M, et al. (2017). Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment.

April 1, 2025 - The US Preventive Services Task Force defines subclinical hypothyroidism as an elevated serum thyrotropin (thyroid-stimulating hormone, TSH) level (> 4.50 mIU/L), but with a normal free thyroxine (T4) level.1 Despite the term subclinical, symptoms may or may not be present, although they tend to be mild and nonspecific. ... Guidelines for diagnosing and managing overt hypothyroidism (in which the TSH level is elevated and the T4 level is low) enjoy broad consensus.2,3 However, whether to treat subclinical hypothyroidism is controversial, especially in people 65 and older.

There are still controversies surrounding SCH and associated risk of various cardiovascular diseases (CVDs), pregnancy outcomes, neuropsychiatric issues, metabolic syndrome, and dyslipidemia. Consensus will require more large randomized clinical studies involving various age groups and medical condition, especially in developing countries. All these efforts will definitely improve our understanding of disease and ultimately patient outcomes. Keywords: Hypothyroidism, Sub Clinical Hypothyroidism, Early Thyroid failure, Risks associated with subclinical hypothyroidism

September 1, 2020 - The BMJ/MAGIC Group states that any benefit from treating subclinical hypothyroidism remains unknown in some patients. Subclinical hypothyroidism increases adverse pregnancy outcomes in retrospective analyses, but evidence is lacking on whether treatment reduces these harms.

June 28, 2024 - Subclinical hypothyroidism (SCH) is diagnosed when peripheral thyroid hormone levels are within the normal range, but thyroid-stimulating hormone (TSH) is mildly elevated. It is thought to affect between 3 and 15% of the population.

September 30, 2021 - However, there are potential downsides to treating subclinical hypothyroidism. There is the risk of overtreatment, which might cause symptoms, such as feeling jittery and insomnia.

Subclinical hypothyroidism or mild thyroid failure is a common problem, with a prevalence of 3% to 8% in the population without known thyroid disease.2,3 The prevalence increases with age and is higher in women.2 After the sixth decade of life, the prevalence in men approaches that of women, ...

The transition from subclinical ... of any symptoms or signs of hypothyroidism.1 Two recent studies have indicated potential detrimental effects of treatment of subclinical hypothyroidism by actually shortening survival.7,8...

The aim of this review was to present data on when levothyroxine treatment should be initiated, and the effects of treatment in subclinical hypothyroidism on symptoms such as weight, quality of life, vitality, cognition, and cardiovascular disease. We also discuss evidence for different thyroid-hormone medications.

February 5, 2025 - Learn why subclinical hypothyroidism (normal T4 levels with elevated TSH) may increase the risk of heart disease.

The risk increases with increasing levels of thyroid stimulating hormone, and is particularly high in patients with TSH levels ≥10.0 mu/L. There is lack of evidence from randomised controlled trials as to whether levothyroxine treatment can prevent these risks, although a large observational study of the UK general practice research database has shown that levothyroxine may reduce the risk of coronary heart disease in younger patients (<70 years). Therefore, the decision whether to treat or not to treat subclinical hypothyroidism should be made after careful consideration of the patient's age, the presence of symptoms, the presence of thyroid antibodies and other risk factors such as cardiovascular disease.

February 15, 1998 - Because patients with subclinical hypothyroidism sometimes have subtle hypothyroid symptoms and may have mild abnormalities of serum lipoproteins and cardiac function, patients with definite and persistent TSH elevation should be considered for thyroid treatment. Levothyroxine, in a dosage that maintains serum TSH levels within the normal range, is the preferred therapy in these patients.

March 12, 2025 - Whilst subclinical shows that there ... vessels, it is still unclear if there are any connections between subclinical hypothyroidism and the increased risk of cardiovascular disease, neuropsychiatric and neuromuscular disorders...

Diagnosing CH can be challenging, particularly in settings where thyroid function tests consist of TSH measurement in isolation24 and another case in which the diagnosis of CH was delayed has been described with serious consequences for the patient concerned.25 In our case, the diagnosis and treatment of his hypothyroidism and adrenal insufficiency were delayed for at least 2 years which is likely to have had a significant effect on his quality of life. A low T4 (or T3) should never be labeled as subclinical hypothyroidism even in the presence of a mildly elevated TSH, which can rarely occur in CH.4 Had this diagnosis not been questioned, this patient's true diagnosis would not have been established and he could have undergone surgery in an adrenal insufficient state with potentially devastating consequences.